Gatifloxacin, gemifloxacin, and moxifloxacin are the newest fluoroquinolones and show excellent in vitro activity against a wide variety of respiratory tract pathogens, many gram-negative aerobic organisms, and Bacteroides fragilis. These agents may be administered as oral and/or intravenous formulations with excellent bioavailability. The pharmacodynamics of these 3 new fluoroquinolones is more favorable than that of levofloxacin or ciprofloxacin for Streptococcus pneumoniae. All 3 agents are approved for the treatment of acute exacerbation of chronic bronchitis and community-acquired pneumonia. In addition, gatifloxacin and moxifloxacin are approved for the treatment of sinusitis. The toxicity of these 3 agents appears to be similar to that of the other fluoroquinolones in terms of gastrointestinal and central nervous system disturbances. All 3 agents have a low risk of phototoxicity, but gemifloxacin is associated with an increased risk of skin rash that is not a photoreaction. These agents can be useful for treatment of bacterial respiratory tract infections in patients who are allergic to b-lactams, but caution must be exercised to avoid the potential for selection of widespread resistance, which may occur with indiscriminate use.
Since the introduction of the first quinolone in 1962, structural modifications have resulted in the production of numerous agents in second-, third-, and fourth-generation fluoroquinolones. In December 1999, the US Food and Drug Administration (FDA) approved moxifloxacin and gatifloxacin. In April 2003, the FDA approved gemifloxacin. These agents are available in parenteral and oral forms; they are the newest generation of quinolone drugs and offer improved coverage against grampositive respiratory pathogens. The mode of action, spectrum of activity, pharmacokinetics and pharmacodynamics, clinical indications, and toxicity of these drugs are reviewed here.
CHEMISTRY
These quinolones have a bicyclic aromatic core with a carbon at position 8, for gatifloxacin and moxifloxacin, and with a nitrogen at position 8, for gemifloxacin. Gatifloxacin, gemifloxacin, and moxifloxacin all demonstrate an N-1 cyclopropyl moiety (figure 1). This confers enhanced activity against anaerobes and potency against gram-positive organisms, especially Streptococcus pneumoniae. It also contributes to reduced photosensitivity and the potential for the emergence of resistance. Because a halide ion is lacking at position 8, the likelihood of photosensitivity is less than that seen with earlier-generation fluoroquinolones, such as sparfloxacin and lomefloxacin [1] .
MODE OF ACTION
All 3 of these fluoroquinolones demonstrate bactericidal activity by binding roughly equivalently to bacterial topoisomerases II (DNA gyrase) and IV. The gyrase is a tetramer composed of 2 subunits, 1 encoded by the gyrA gene and 1 encoded by the gyrB gene. By binding to these enzymes, the fluoroquinolones interfere with DNA replication, repair, and transcription, resulting in bacterial death. The ability to target both enzymes has been promoted as a major advantage of these agents in preventing or delaying the emergence of resistance. If a singlestep mutation occurs in one targeted enzyme, the ability of Figure 1 . Chemical structures of gatifloxacin, gemifloxacin, and moxifloxacin gatifloxacin, gemifloxacin, or moxifloxacin to target another enzyme should prevent the occurrence of high-level resistance, unless another mutation occurs [2] . This remains controversial for a variety of reasons [3] .
ANTIMICROBIAL ACTIVITY
The antimicrobial activity of gatifloxacin, gemifloxacin, and moxifloxacin is summarized and compared with that of ciprofloxacin and levofloxacin in table 1 [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . All 3 new drugs possess enhanced activity against gram-positive bacteria, most notably against penicillin-susceptible and penicillin-resistant strains of S. pneumoniae. Gatifloxacin is twice as active as levofloxacin, and moxifloxacin is 8 times as active as levofloxacin. Gemifloxacin appears to be more active than moxifloxacin for gram-positive organisms, but it has higher protein binding and lower serum levels. Thus, it falls within the same range of activity. The 3 new quinolones have enhanced activity against Staphylococcus aureus, compared with ciprofloxacin. Unfortunately, the new agents still demonstrate less activity against methicillin-resistant strains than against methicillin-susceptible strains. Activity against methicillin-resistant strains is poor, because inhibitory concentrations often exceed achievable serum concentrations.
The activity of these fluoroquinolones against gram-negative microorganisms is preserved, but they are less active against gram-negative bacteria than is ciprofloxacin. Specifically, these agents are not as active against Pseudomonas aeruginosa as is ciprofloxacin. For other respiratory pathogens, including Moraxella catarrhalis, Haemophilus influenzae, and Legionella pneumophila, both older and newer fluoroquinolones demonstrate excellent activity. For Chlamydia pneumoniae and Mycoplasma pneumoniae, gatifloxacin, gemifloxacin, and moxifloxacin appear to be comparable to one another and superior to ciprofloxacin. All 3 should all be clinically equivalent, because they have similar pharmacodynamic properties. Gatifloxacin and moxifloxacin demonstrate enhanced activity against Bacteroides fragilis, compared with ciprofloxacin, but they are not quite as effective as trovafloxacin against this organism.
PHARMACOKINETICS AND PHARMACODYNAMICS
Fluoroquinolones demonstrate concentration-dependent killing. The ratio of the peak concentration (C max ) to the MIC and of the area under the curve (AUC) to the MIC appear to be the parameters that best correlate with clinical efficacy. Which of these best correlates with efficacy has been controversial because of differences in the definition of an optimal end point, microbiological or clinical, and the lack of a robust database to optimally define the predictive value of these pharmacodynamic parameters [14] .
The pharmacokinetic and pharmacodynamic characteristics of gatifloxacin, gemifloxacin, and moxifloxacin are compared with those of ciprofloxacin and levofloxacin in table 2 [8, [14] [15] [16] . It should be recognized that simple single-point MIC 90 values may not accurately represent effective drug activity, because of the pharmacokinetic variability that exists in patient populations [17] . Use of Monte Carlo simulation is an iterative stochastic process that estimates the probability of achieving a pharmacodynamic outcome in a patient population of interest. It provides better comparative pharmacodynamic end-point comparisons among drugs [18, 19] .
The dose for both oral and intravenous preparations is 400 mg for gatifloxacin and moxifloxacin [15] . The bioavailability of the oral formulation of gemifloxacin is ∼61% that of the intravenous formulation, and the normal dosage is 320 mg po daily [8] .
All 3 fluoroquinolones penetrate tissues well. Concentration in the respiratory tract (bronchial mucosa, lung epithelial lining, and sinus mucosa) exceed serum levels, and cellular penetration in alveolar macrophages is greater than serum levels by 26-fold for gatifloxacin, 90-fold for gemifloxacin, and 21-fold for moxifloxacin [8, 15] . CSF levels of gatifloxacin are 36% of serum levels [16] . CSF levels of moxifloxacin were 34%-78% of serum levels in inflamed meninges in animal models [20] . In experimental meningitis models, gemifloxacin CSF levels were 22%-33% of serum levels [21] . The actual concentration in humans with meningitis and inflammation is expected to be even higher. Controversy remains with regard to optimal pharmacodynamically defined breakpoints. Ideally, the drug exposure that kills infecting organisms, prevents emergence of resistance, and does not cause a toxic reaction is most desirable. If the freedrug AUC/MIC ratio is 133.7, the probability of a favorable clinical outcome is quite high (1100%) for patients infected with gram-positive organisms [15] .
Using this cutoff criterion (AUC/MIC ratio, 133.7), ciprofloxacin clearly fares poorly against gram-positive organisms, whereas gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin all exceed this threshold. However, levofloxacin barely achieves the goal, and, for isolates with MICs of у2.0 mg/mL, levofloxacin is inadequate.
Gatifloxacin is excreted in the urine unchanged, via glomerular filtration alone, resulting in 80%-95% recovery of an administered dose by this route. The level of fecal elimination is very low. Gemifloxacin elimination occurs by both renal (60%) and hepatic (40%) routes, and active tubular secretion is evident in the kidney. Moxifloxacin is eliminated predominantly by glucuronide and sulfate conjugation.
APPROVED CLINICAL INDICATIONS
The FDA has approved the use of gatifloxacin and moxifloxacin for acute sinusitis, chronic bronchitis, and community-acquired pneumonia. Use of gemifloxacin has been approved for acute exacerbation of chronic bronchitis and mild-to-moderate community-acquired pneumonia. All 3 agents would be considered acceptable for outpatient and inpatient treatment of mild-tomoderate pneumonia on the basis of the consensus statement from the Infectious Diseases Society of America on treatment of this condition [22] . The use of fluoroquinolones in respiratory tract infections must be balanced against concern for emergence of fluoroquinolone resistance among S. pneumoniae isolates as a consequence of increased use. The increasing occurrence of b-lactam resistance among S. pneumoniae isolates prompted the recommendation that fluoroquinolones be among the first-line agents in the empirical treatment of lower respiratory tract infections. Pharmacodynamic considerations instead suggest that penicillin or amoxicillin at high doses should still be considered the drugs of choice [23] . In addition to respiratory tract infections, gatifloxacin has received approval for skin infections, cystitis, pyelonephritis, complicated urinary tract infections, and gonorrhea. These approvals have been based on the results of prospective, randomized, FDA-approved phase 3 trials that compared the agents to alternative drugs generally used in the treatment of the infection studied [24, 25] .
ADDITIONAL INDICATIONS
There are other clinical indications for which these agents may be considered but for which FDA approval is lacking. One such indication is diabetic foot infections in which a polymicrobial etiology is suspected. Because of the improved anaerobic activity of gatifloxacin, gemifloxacin, and moxifloxacin, compared with ciprofloxacin, monotherapy with one of these agents is a tempting option, although there is little clinical experience to date. Caution should be exercised, because S. aureus, a common pathogen in diabetic foot infection, may be incompletely eradicated by fluoroquinolones, allowing the selection of resistant mutants. Clonal expansion of resistant strains has been reported for Escherichia coli and other gram-negative bacteria, resulting in widespread resistance to fluoroquinolones in general [26] . Off-label use may be associated with the emergence of resistance and increased cost.
Ongoing controversy remains about the use of quinolones to treat pediatric patients, for whom there are a variety of proposed indications, including otitis media. Use of quinolones has been well received in the management of bronchopulmonary exacerbations due to P. aeruginosa in patients with cystic fibrosis. However, this is not relevant for newer fluoroquinolones, which have less activity than ciprofloxacin against P. aeruginosa. Because of their enhanced pharmacokinetics and dynamics, these drugs might also be considered for use in preventing Neisseria meningitidis meningitis, although the use of oral ciprofloxacin alone appears to be very effective [27, 28] . Treatment of meningitis may become an additional consideration.
The use of oral monotherapy with these agents in a oncedaily dosing regimen to treat intra-abdominal infections is under investigation. However, these agents exhibit poor activity against enterococci, and, if enterococci are suspected, ampicillin or vancomycin must be added to the regimen.
Use of these fluoroquinolones to treat polymicrobial bone and joint infections is worth consideration. However, again, the suboptimal experience with use of fluoroquinolones as antistaphylococcal agents needs to be remembered. Caution is advised in the use of these agents as single-drug therapy for serious staphylococcal infections.
As these agents continue to be evaluated, it can be anticipated that new indications will be identified. Specifically, the role of these drugs in the treatment of meningitis and pediatric infections, such as otitis media, will require additional research.
TOXICITY PROFILE
The adverse events associated with these 3 new fluoroquinolones appear to be similar to those associated with established agents, with some differences in frequency [8, 24, 29, 30] . Overall, these agents have been used to treat 112 million patients and must be considered safe and well tolerated, not only as a class, but as individual agents. The most common side effects include gastrointestinal disturbance with nausea (4%-8% of patients), vomiting (2%), diarrhea (4%-5%), and abdominal pain (2%).
CNS side effects occur at a rate of 2%-4%, manifested as headache (2%-4% of patients), dizziness (2%-3%), and other symptoms (!1%), including confusion, agitation, insomnia, depression, somnolence, vertigo, light-headedness, and tremors. Seizures are rare. Some quinolones displace g-aminobutyric acid (GABA) or compete with GABA binding at the receptor sites within the CNS. Substitution of 7-piperazinyl-or 7-pyrrolidinyl-containing compounds, such as gatifloxacin, gemifloxacin, and moxifloxacin, is associated with reduced seizure-causing potential. Administration of nonsteroidal antiinflammatory drugs concurrently with certain quinolones has been linked to an increase in the possibility of seizures [31] .
Phototoxicity occurs rarely, and experience reported to date suggests that, for gatifloxacin, gemifloxacin, and moxifloxacin, phototoxic adverse events occur at a lower rate than with widely used fluoroquinolones, such as ciprofloxacin and levofloxacin.
In an analysis of data from 2,235,000 patients who were treated with moxifloxacin, no cases of arthritis or tendonitis were found [16] . Nevertheless, a clinician should consider alternative therapies when treating athletes who are at risk for tendon rupture. Use of gemifloxacin will continue to be monitored for an apparent increased risk of skin rash (3%), especially in women !40 years of age who receive 17 days of therapy [8] .
The FDA-approved prescribing information for gatifloxacin has been updated to include stronger precautions against possible disturbances of glucose homeostasis [32] . Reports in the literature of possible drug-drug interactions between ciprofloxacin and glyburide suggest that the potential for a drug class effect exists that should be monitored [33] . Package inserts for all marketed fluoroquinolones mention such potential interactions.
Concern about hepatotoxicity does not seem supported by postmarketing (phase 4) surveillance conducted by the manufacturers and reported to the FDA. None of the 3 new fluoroquinolones has been associated with the serious hepatotoxicity reported to occur with use of trovafloxacin. Minor increases (up to 3 times normal) in liver transaminase levels may occur in up to 1% of patients [8, 16, 24, 29, 30] .
Another area of concern is cardiac toxicity, with ratecorrected electrocardiographic QT interval (QTc) prolongation and the possible development of fatal ventricular arrhythmias, such as torsades de pointes (multifocal ventricular tachyarrhythmias associated with QTc prolongation). Cardiac toxicity probably represents a fluoroquinolone class effect with a presumed mechanism of blockade of the human ether a-gogo-related gene potassium channel [34] . The QTc interval prolongation associated with gatifloxacin, gemifloxacin, and moxifloxacin is less than that seen with sparfloxacin and comparable to that with levofloxacin. There have been only rare reports of torsades de pointes in association with gatifloxacin (3 cases) and moxifloxacin (1 case) [34] . No cases of torsades de pointes have yet been reported for gemifloxacin. Although QTc prolongation is usually within the range of normal variation, increases above the upper limits of normal can occur in patients with other risk factors. Caution in the use of these drugs concomitantly with antiarrhythmic drugs or macrolides should be exercised. Other risk factors include underlying cardiac disease, hypokalemia, and hypomagnesemia
The collective experience with gatifloxacin, gemifloxacin, and moxifloxacin suggests that the side effects of these 3 drugs are very similar and are comparable to those of older members of this class. Overall, discontinuation rates have been !3% [4, 8, 24, 25, 29, 30] .
In summary, the new fluoroquinolones gatifloxacin, gemifloxacin, and moxifloxacin all demonstrate improved in vitro activity against gram-positive organisms, pharmacokinetics, and pharmacodynamics when compared with levofloxacin and ciprofloxacin. These agents have some differences, but no drug emerges as having any clinical advantage among the 3 agents. To date, all 3 drugs appear to be safe. There is still concern about the potential for emergence of resistance if these agents become widely and indiscriminately used in the management of upper respiratory tract infections, in which a bacterial etiology seems less likely. The future of the fluoroquinolones may depend on how judiciously we use these new agents [35] .
